PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof

US11377477B2 · kind B2 · utility

Assignee

• Xencor, Inc. · US

Inventors

• Matthew Bernett · Monrovia, US
• John Desjarlais · Pasadena, US
• Michael Hedvat · Sylvia Park, US
• Suzanne Schubbert · Long Beach, US
• Christine Bonzon · Los Angeles, US
• Rumana Rashid · Temple City, US
• Rajat Varma · Hamden, US

Key dates

• Filing date: Oct 11, 2019
• Grant date: Jul 5, 2022
• Expiry date: Oct 11, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/32
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to novel PD-1 targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins are administered to a patient to treat cancer. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins are administered in combination with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins do not compete with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab for antigen binding.